Drugs that contain Regorafenib

1. Drug name - STIVARGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(3 months ago)

US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(8 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

CN101257903A BAYER HLTHCARE Combination Therapy Comprising A Diaryl Urea Compound And A Pi3, Akt Kinase Or Mtor Inhibitors (Rapamycins) For Cancer Treatment
Mar, 2011

(11 years ago)

CN100522934C BAYER HLTHCARE Acardite As Raf Kinase Inhibitors With Omega-Carboxy Aryl Substituted
Jan, 2020

(2 years ago)

CN1721397A BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN1219764C BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN1341098A BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN102816113B BAYER HLTHCARE Fluorin Generation [Omega]-Carboxylic Aryl Ureas For Treating And Preventing Symptoms And Disease
Jul, 2024

(1 year, 9 months from now)

CN1856469B BAYER HLTHCARE [Omega]-Carboxylic Aryl Phenylurea For The Treatment And Prevention Of Diseases And Disease Symptoms
Jul, 2024

(1 year, 9 months from now)

CN102816113A BAYER HLTHCARE Fluoro Omega-Carboxyaryl Diphenyl Urea For Treating And Preventing Disease And Disease Symptom
Jul, 2024

(1 year, 9 months from now)

CN1856469A BAYER HLTHCARE For The Treatment And Prevention Of Diseases And Disease Symptoms- Carboxylic Aryl Ureas
Jul, 2024

(1 year, 9 months from now)

CN101547903A BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

CN101547903B BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

IN215758B BAYER HLTHCARE Carboxyaryl Substituted Diphenyl Ureas
Jan, 2020

(2 years ago)

IN200100799P3 BAYER HLTHCARE Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

IN200600402P1 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Jul, 2024

(1 year, 9 months from now)

IN240207B BAYER HLTHCARE A Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea Compound Or A Salt, An Isolated Stereoisomer Thereof
Jul, 2024

(1 year, 9 months from now)

EP1690853A1 BAYER HLTHCARE Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1690853B1 BAYER HLTHCARE Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

EP2298311B1 BAYER HLTHCARE W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985B1 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985A1 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985A4 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP2298311A1 BAYER HLTHCARE W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1140840B1 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1140840A1 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1140840A4 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1379507A1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

EP1379507B1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

EP2097381B1 BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

EP2097381A1 BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

EP1663978B1 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Aug, 2028

(5 years from now)

EP1663978A2 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors Jun, 2030

(7 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate Apr, 2031

(8 years from now)

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.